Browse studies

Find your next paid study

9 recruiting studies matching your filters

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease…

Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more

Estimated

~$10 – $1,125

AstraZenecaNCT06465810

Phase 3

TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Ev…

Transthyretin Amyloidosis With Cardiomyopathy

Estimated

~$10 – $8,750

Alnylam PharmaceuticalsNCT07052903

Post-Authorisation Safety Study: A Cohort Event Monitoring Study to Characterise the Use of Eplontersen in Patients With Prior Liver Transplant and Pre-existing Severe Hepatic Impairment and to Assess Long-term Safety Among All New Users of Eplontersen (sTTRing)

The aim of this observational cohort study is to characterise use of eplontersen in patients with prior liver transplant or with pre-existing severe hepatic im…

Transthyretin AmyloidosisTransthyretin Amyloidosis With CardiomyopathyTransthyretin Amyloidosis With Polyneuropathy

Estimated

~$10 – $1,125

AstraZenecaNCT07654855

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting

The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-C…

Transthyretin Amyloidosis With Cardiomyopathy

Estimated

~$10 – $1,050

Alnylam PharmaceuticalsNCT07358078

Observational

Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction

Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, …

Transthyretin AmyloidosisHeart FailureHeart Failure, Diastolic+1 more

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT05577819

Phase 3

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like subs…

AmyloidosisAmyloid CardiomyopathyTransthyretin Amyloidosis+3 more

Estimated

~$10 – $8,750

Eidos Therapeutics, a BridgeBio companyNCT06563895

Phase 4

An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)AmyloidosisAmyloid Cardiomyopathy+1 more

Estimated

~$10 – $8,750

Eidos Therapeutics, a BridgeBio companyNCT07695701

Phase 2

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the d…

AmyloidosisTransthyretin Amyloidosis

Estimated

~$10 – $6,250

Oregon Health and Science UniversityNCT05758493

Phase 3

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Estimated

~$10 – $8,750

Intellia TherapeuticsNCT06128629